間質性肺炎合併非小細胞肺癌に対してドセタキセル＋ラムシルマブ併用療法で加療を行った症例群に関する後方視的検討-Reference-Cited by-同舟云学术

間質性肺炎合併非小細胞肺癌に対してドセタキセル＋ラムシルマブ併用療法で加療を行った症例群に関する後方視的検討

Published:2023-12-20 Issue:7 Volume:63 Page:946-952
ISSN:0386-9628
Container-title:Haigan
language:en
Short-container-title:JJLC

Author:

Taguchi Yoshihiro¹,Hirayama Ryutaro¹,Katayama Issei¹,Yamamoto Haruka¹,Nagai Atsushi¹,Ueda So¹,Hirose Miyu¹,Sugimoto Eiji¹,Nakamura Yukihiro¹,Yamaguchi Osamu¹

Affiliation:

1. Department of Cardiology, Pulmonology, Hypertension & Nephrology, Ehime University Graduate School of Medicine

Publisher

Japan Lung Cancer Society

Subject

Pulmonary and Respiratory Medicine,Oncology

Link

https://www.jstage.jst.go.jp/article/haigan/63/7/63_946/_pdf

Reference24 articles.

1. 1. Kenmotsu H, Yoh K, Mori K, Ono A, Baba T, Fujiwara Y, et al. Phase II study of nab-paclitaxel＋carboplatin for patients with non-small-cell lung cancer and interstitial lung disease. Cancer Sci. 2019; 110: 3738-3745.

2. 2. Wang Y, Miao L, Hu Y, Zhou Y. The efficacy and safety of first-line chemotherapy in patients with non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis. Front Oncol. 2020; 10: 1636.

3. 3. Igawa S, Yokoba M, Takakura A, Hosotani S, Nakahara Y, Sato T, et al. Real-world evaluation of second line chemotherapy for patients with advanced non-small cell lung cancer harboring preexisting interstitial lung disease. Invest New Drugs. 2022; 40: 182-189.

4. 4. 日本肺癌学会, 編集. 肺癌診療ガイドライン悪性胸膜中皮腫・胸腺腫瘍含む 2022年度版. 東京: 金原出版; 2022: 235-239.

5. 5. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018; 198: e44-e68.